RASSF1A in maternal plasma as a molecular marker of preeclampsia

Prenatal Diagnosis

Volumn 33, Issue 7, 2013, Pages 682-687

  Papantoniou, Nikolas ^a   Bagiokos, Vassilis ^a   Agiannitopoulos, Kostantinos ^a   Kolialexi, Aggeliki ^a,b   Destouni, Aspasia ^a,b   Tounta, Georgia ^a   Kanavakis, Emmanuel ^a   Antsaklis, Aris ^a   Mavrou, Ariadni ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b St Sophia's Children's Hospital   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A;

ACTB GENE; ADULT; ARTICLE; BLOOD SAMPLING; CELL FREE SYSTEM; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DNA METHYLATION; FEMALE; GENE; GESTATIONAL AGE; HUMAN; MATERNAL PLASMA; PREDICTIVE VALUE; PREECLAMPSIA; PREGNANT WOMAN; PRIORITY JOURNAL; RASSF1A GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; TUMOR SUPPRESSOR GENE;

BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; DNA; DNA METHYLATION; FEMALE; FETUS; GESTATIONAL AGE; HUMANS; PLACENTA; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY TRIMESTER, FIRST; REAL-TIME POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDIES; TUMOR SUPPRESSOR PROTEINS;

EID: 84880036656     PISSN: 01973851     EISSN: 10970223     Source Type: Journal    
DOI: 10.1002/pd.4093     Document Type: Article

References (40)

1. Sibai B, Dekker G, Kupferminc M. Pre-eclampsia. Lancet 2005;365:785-99.
2. Stekkinger E, Zandstra M, Peeters LL, Spaanderman ME. Early-onset preeclampsia and the prevalence of postpartum metabolic syndrome. Obstet Gynecol 2009;114:1076-84.
3. Plasencia W, Maiz N, Bonino S, et al. Uterine artery Doppler at 11+0 to 13+6weeks in the prediction of pre-eclampsia. Ultrasound Obstet Gynecol 2007;30:742-9.
4. Duckitt K, Harrington D. Risk factors for pre-eclampsia at antenatal booking: systematic review of controlled studies. BMJ 2005;330:565.
5. Goetzinger KR, Singla A, Gerkowicz S, et al. Predicting the risk of pre-eclampsia between 11 and 13weeks' gestation by combining maternal characteristics and serum analytes, PAPP-A and free beta-hCG. Prenat Diagn 2010;30:1138-42.
6. Poon LC, Kametas NA, Maiz N, et al. First-trimester prediction of hypertensive disorders in pregnancy. Hypertension 2009;53:812-8.
7. Ong CY, Liao AW, Spencer K, et al. First trimester maternal serum free beta human chorionic gonadotrophin and pregnancy associated plasma protein A as predictors of pregnancy complications. BJOG 2000;107:1265-70.
8. Pilalis A, Souka AP, Antsaklis P, et al. Screening for pre-eclampsia and fetal growth restriction by uterine artery Doppler and PAPP-A at 11-14weeks' gestation. Ultrasound Obstet Gynecol 2007;29:135-40.
9. Laigaard J, Sorensen T, Placing S, et al. Reduction of the disintegrin and metalloprotease ADAM12 in preeclampsia. Obstet Gynecol 2005;106:144-9.
10. Spencer K, Cowans NJ, Stamatopoulou A. ADAM12s in maternal serum as a potential marker of pre-eclampsia. Prenat Diagn 2008;28:212-6.
11. Poon LC, Chelemen T, Granvillano O, et al. First-trimester maternal serum a disintegrin and metalloprotease 12 (ADAM12) and adverse pregnancy outcome. Obstet Gynecol 2008;112:1082-90.
12. Sifakis S, Akolekar R, Kappou D, et al. Maternal serum insulin-like growth factor-I at 11-13weeks in preeclampsia. Prenat Diagn 2010;30:1026-31.
13. Sifakis S, Akolekar R, Mantas N, et al. Maternal serum human placental growth hormone (hPGH) at 11 to 13weeks of gestation in preeclampsia. Hypertens Pregnancy 2011;30:74-82.
14. Sifakis S, Akolekar R, Kappou D, et al. Maternal serum insulin-like growth factor-binding protein-3 (IGFBP-3) at 11-13weeks in preeclampsia. J Hum Hypertens 2012;26:253-8.
15. Maron JL, Johnson KL, Slonim D, et al. Gene expression analysis in pregnant women and their infants identifies unique fetal biomarkers that circulate in maternal blood. J Clin Invest 2007;117:3007-19.
16. Tuohey L, Macintire K, Ye L, et al. PLAC4 is upregulated in severe early onset preeclampsia and upregulated with syncytialisation but not hypoxia. Placenta 2013;34(3):256-60.
17. Lo YM, Corbetta N, Chamberlain PF, et al. Presence of fetal DNA in maternal plasma and serum. Lancet 1997;350:485-7.
18. Ishihara N, Matsuo H, Murakoshi H, et al. Increased apoptosis in the syncytiotrophoblast in human term placentas complicated by either preeclampsia or intrauterine growth retardation. Am J Obstet Gynecol 2002;186:158-66.
19. Lo YM, Leung TN, Tein MS, et al. Quantitative abnormalities of fetal DNA in maternal serum in preeclampsia. Clin Chem 1999;45:184-8.
20. Leung TN, Zhang J, Lau TK, et al. Increased maternal plasma fetal DNA concentrations in women who eventually develop preeclampsia. Clin Chem 2001;47:137-9.
21. Zhong XY, Holzgreve W, Hahn S. The levels of circulatory cell free fetal DNA in maternal plasma are elevated prior to the onset of preeclampsia. Hypertens Pregnancy 2002;21:77-83.
22. Levine RJ, Qian C, Leshane ES, et al. Two-stage elevation of cell-free fetal DNA in maternal sera before onset of preeclampsia. Am J Obstet Gynecol 2004;190:707-13.
23. Farina A, Sekizawa A, Iwasaki M, et al. Total cell-free DNA (beta-globin gene) distribution in maternal plasma at the second trimester: a new prospective for preeclampsia screening. Prenat Diagn 2004;24:722-6.
24. Sifakis S, Zaravinos A, Maiz N, et al. First-trimester maternal plasma cell-free fetal DNA and preeclampsia. Am J Obstet Gynecol 2009;201:472 e1-7.
25. Hromadnikova I, Zejskova L, Kotlabova K, et al. Quantification of extracellular DNA using hypermethylated RASSF1A, SRY, and GLO sequences - evaluation of diagnostic possibilities for predicting placental insufficiency. DNA Cell Biol 2010;29:295-301.
26. Farina A, Sekizawa A, Sugito Y, et al. Fetal DNA in maternal plasma as a screening variable for preeclampsia. A preliminary nonparametric analysis of detection rate in low-risk nonsymptomatic patients. Prenat Diagn 2004;24:83-6.
27. Vodicka R, Vrtel R, Dusek L, et al. Refined fluorescent STR quantification of cell-free fetal DNA during pregnancy in physiological and Down syndrome fetuses. Prenat Diagn 2008;28:425-33.
28. Chan KC, Ding C, Gerovassili A, et al. Hypermethylated RASSF1A in maternal plasma: a universal fetal DNA marker that improves the reliability of noninvasive prenatal diagnosis. Clin Chem 2006;52:2211-8.
29. Chiu RW, Chim SS, Wong IH, et al. Hypermethylation of RASSF1A in human and rhesus placentas. Am J Pathol 2007;170:941-50.
30. Agathanggelou A, Cooper WN, Latif F. Role of the Ras-association domain family 1 tumor suppressor gene in human cancers. Cancer Res 2005;65:3497-508.
31. Zeybek YG, Gunel T, Benian A, et al. Clinical evaluations of cell-free fetal DNA quantities in pre-eclamptic pregnancies. J Obstet Gynaecol Res 2013;39(3):632-40.
32. Kaufmann I, Rusterholz C, Hosli I, et al. Can detection of late-onset PE at triage by sflt-1 or PlGF be improved by the use of additional biomarkers? Prenat Diagn 2012;32:1288-94.
33. Lazar L, Rigo J, Jr., Nagy B, et al. Relationship of circulating cell-free DNA levels to cell-free fetal DNA levels, clinical characteristics and laboratory parameters in preeclampsia. BMC Med Genet 2009;10:120.
34. Barrett AN, Zimmermann BG, Wang D, et al. Implementing prenatal diagnosis based on cell-free fetal DNA: accurate identification of factors affecting fetal DNA yield. PLoS One 2011;6:e25202.
35. Holzgreve W, Ghezzi F, Di Naro E, et al. Disturbed feto-maternal cell traffic in preeclampsia. Obstet Gynecol 1998;91:669-72.
36. Knight M, Redman CW, Linton EA, Sargent IL. Shedding of syncytiotrophoblast microvilli into the maternal circulation in pre-eclamptic pregnancies. Br J Obstet Gynaecol 1998;105:632-40.
37. Crowley A, Martin C, Fitzpatrick P, et al. Free fetal DNA is not increased before 20weeks in intrauterine growth restriction or pre-eclampsia. Prenat Diagn 2007;27:174-9.
38. Bauer M, Hutterer G, Eder M, et al. A prospective analysis of cell-free fetal DNA concentration in maternal plasma as an indicator for adverse pregnancy outcome. Prenat Diagn 2006;26:831-6.
39. Alberry MS, Maddocks DG, Hadi MA, et al. Quantification of cell free fetal DNA in maternal plasma in normal pregnancies and in pregnancies with placental dysfunction. Am J Obstet Gynecol 2009;200:98 e1-6.
40. McIntire DD, Leveno KJ. Neonatal mortality and morbidity rates in late preterm births compared with births at term. Obstet Gynecol 2008;111:35-41.